Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-11-29

Clinical Trial Update: Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis [NA]

View source ↗

Summary

Completed clinical trial evaluating ambrisentan in combination with an antifibrotic agent for diffuse systemic sclerosis; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ambrisentan (Ambrisentan)

Snippet

Sponsor: University of Pennsylvania | Conditions: Systemic Sclerosis, Scleroderma | NA | Status: COMPLETED | Results posted: 2018-11-29